...
首页> 外文期刊>Digestive Diseases and Sciences >Risk of Clostridium difficile Infection with Systemic Antimicrobial Therapy Following Successful Fecal Microbiota Transplant: Should We Recommend Anti-Clostridium difficile Antibiotic Prophylaxis?
【24h】

Risk of Clostridium difficile Infection with Systemic Antimicrobial Therapy Following Successful Fecal Microbiota Transplant: Should We Recommend Anti-Clostridium difficile Antibiotic Prophylaxis?

机译:成功粪便微生物群移植后系统抗菌治疗梭菌感染的风险:我们应该建议抗蛋白腹菌抗生素预防吗?

获取原文
获取原文并翻译 | 示例
           

摘要

IntroductionThe risk of a new Clostridium difficile infection (CDI) after FMT is unknown if non-CDI antibiotics are required. It is uncertain if anti-CDI prophylaxis or probiotics would reduce risk. We therefore aimed to compare the risk of CDI with and without antibiotic exposure and the benefit of concomitant anti-CDI antibiotic or probiotic prophylaxis.MethodsThis is a multicenter retrospective study carried out at three large FMT referral centers of patients who underwent FMT for recurrent CDI. Patients were assessed for antibiotic use, as well as concomitant use of prophylactic anti-CDI antibiotics or probiotics. Time to CDI recurrence after FMT was evaluated using the Kaplan-Meier method.ResultsA total of 404 patients were included: 63% were females, with a mean age of 61.318.8years. Mean length of post-FMT follow-up was 18.1 +/- 11.9months (range 2.2-45.2). Among the entire cohort 8.1% (n=33) experienced a CDI recurrence. Overall, 111 patients (27.4%) used a non-CDI antibiotic, of which 16.2% (n=18) experienced a CDI recurrence. Patients who used non-CDI antibiotics were more likely to develop CDI (HR 8.44, 95% CI 4.21-16.93, p<0.001). The risk of CDI recurrence was not different between patients who received anti-CDI antibiotic prophylaxis to those who did not (HR=1.88, 95% CI 0.72-4.86, p=0.2); however, probiotic prophylaxis was associated with a greater risk of CDI recurrence (HR=2.65, 95% CI 1.02-6.86, p=0.045).Conclusion Non-CDI antibiotic use was not uncommon after successful FMT and significantly increased the risk of a new episode of CDI. In this study, we found that the prophylactic use of anti-CDI antibiotics or probiotics was not protective.
机译:如果需要非CDI抗生素,则FMT在FMT后概述新的Clostridium艰难梭菌感染(CDI)的风险。如果抗CDI预防或益生菌会降低风险是不确定的。因此,我们旨在将CDI与抗生素暴露的风险进行比较,并且伴随抗CDI抗生素或益生菌预防的益处。方法是在三种大型FMT转诊中心进行的多中心回顾性研究,该研究进行了用于复发CDI的FMT。评估患者的抗生素使用,以及伴随着预防性抗CDI抗生素或益生菌的使用。使用Kaplan-Meier方法评估FMT后CDI复发的时间。患有404名患者的总共有404名患者:63%是女性,平均年龄为61.318.8岁。 PERT-FMT后续行动的平均长度为18.1 +/- 11.9个月(范围2.2-45.2)。在整个群组中,8.1%(n = 33)经历了CDI复发。总体而言,111名患者(27.4%)使用了非CDI抗生素,其中16.2%(n = 18)经历了CDI复发。使用非CDI抗生素的患者更容易发生CDI(HR 8.44,95%CI 4.21-16.93,P <0.001)。接受抗CDI抗生素预防的患者对没有(HR = 1.88,95%CI 0.72-4.86,P = 0.2)的患者的患者之间的风险与抗CDI抗生素预防患者之间没有什么不同;然而,益生菌预防与CDI复发的风险更大(HR = 2.65,95%CI 1.02-6.86,P = 0.045)。结论非CDI抗生素使用后成功的FMT后并不罕见,并且显着增加了新的风险CDI剧集。在这项研究中,我们发现预防抗CDI抗生素或益生菌的使用不受保护性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号